Jump to content

Viscosupplementation For Osteoarthritis


Original Editor ­ - Jasmien Cools Top Contributors - Lucinda hampton, Admin, Vidya Acharya, Jasmien Cools, 127.0.0.1, Daphne Jackson, Evan Thomas, WikiSysop and Vijay Rajaram


Introduction

Viscosupplementation represents an adjunctive therapeutic intervention for patients with osteoarthritis (OA) who demonstrate inadequate response to exercise therapy and conservative management.[1][2] Understanding the appropriate timing and clinical indications for this intervention enables physiotherapists to optimise patient outcomes by establishing a therapeutic window that facilitates engagement in active rehabilitation protocols.

Mechanism of Action

Viscosupplementation involves the ultrasound-guided intra-articular injection of hyaluronic acid (HA) to restore the rheological properties of synovial fluid in osteoarthritic joints.[3] Hyaluronic acid is an endogenous glycosaminoglycan that constitutes a principal component of synovial fluid and the cartilage extracellular matrix. In osteoarthritic joints, both the concentration and molecular weight of HA are diminished, resulting in compromised lubrication, elevated friction coefficients, and nociceptive stimulation.[4] Therapeutic HA administration aims to restore optimal synovial fluid viscosity and elasticity through multiple biomechanical and biochemical mechanisms.[5]

HA Preparations

Low Molecular Weight Formulations: Naturally-derived preparations (e.g., Hyalgan) requiring serial administration of 3-5 weekly injections with relatively shorter duration of therapeutic effect.

High Molecular Weight Formulations: Cross-linked synthetic preparations (e.g., Synvisc, Durolane) permitting single-injection protocols with extended intra-articular residence time (up to 6 months) and demonstrated superior clinical outcomes.[6]

Clinical Indications for Viscosupplementation

Candidate Selection Criteria

Viscosupplementation is indicated for patients with mild to moderate osteoarthritis of the knee, hip, or shoulder joints who demonstrate insufficient response to conservative therapeutic interventions.[7] Clinical recommendation is appropriate when patients demonstrate:

  • Completion of a minimum 6-8 week structured physiotherapy programme[8]
  • Persistent moderate to severe pain intensity (Visual Analogue Scale >4/10) despite conservative interventions
  • Functional limitations that impede participation in rehabilitation activities
  • Radiographic evidence of mild to moderate degenerative changes (Kellgren-Lawrence grades 2-3)[9]
  • Demonstrated motivation and capacity to engage in concurrent and post-intervention physiotherapy

Joint-Specific Evidence Base

Knee Osteoarthritis: Systematic reviews and meta-analyses demonstrate that intra-articular HA provides statistically significant and clinically meaningful improvements in pain and functional outcomes at 3-6 months post-intervention compared to placebo controls.[10][11] High molecular weight formulations demonstrate superior efficacy profiles.

Hip Osteoarthritis: High molecular weight HA formulations provide sustained pain reduction and functional improvement extending to 12 months post-intervention.[12] When integrated with structured physiotherapy interventions, viscosupplementation may delay the necessity for total hip arthroplasty.[13]

Shoulder Osteoarthritis: While evidence supports potential efficacy of viscosupplementation, physiotherapy interventions demonstrate superior therapeutic effects on disability reduction and pain management and should maintain primacy in the treatment hierarchy.[14]

Contraindications

Absolute Contraindications: Active septic arthritis, cutaneous infection at the proposed injection site, documented hypersensitivity to hyaluronic acid preparations

Relative Contraindications: Advanced osteoarthritis (Kellgren-Lawrence grade 4), inflammatory arthropathies, insufficient trial of conservative therapeutic interventions

Systematic Assessment for Referral

Comprehensive evaluation should incorporate:

  1. Pain Characteristics: Visual Analogue Scale >4/10 despite conservative interventions, activity-related pain patterns limiting functional capacity
  2. Treatment History: Documentation of 6-8 weeks of supervised physiotherapy, adherence to prescribed home exercise programmes, trial of appropriate pharmacological management
  3. Functional Status: Quantifiable impairments in activities of daily living, reduced exercise tolerance, restrictions in occupational or recreational activities
  4. Imaging Findings: Radiographic confirmation of osteoarthritic changes, preferential candidacy for Kellgren-Lawrence grades 2-3
  5. Patient Factors: Realistic treatment expectations, demonstrated commitment to ongoing physiotherapy participation

Integration with Physiotherapy Practice

Viscosupplementation should be positioned as a complementary intervention rather than a replacement for evidence-based physiotherapy interventions.[15][16]

Post-Injection Rehabilitation Protocol

Phase 1 (Weeks 1-2): Protected Activity Period

  • Relative rest for 24-48 hours post-injection
  • Gentle range of motion exercises within pain-free ranges
  • Avoidance of high-impact loading activities
  • Systematic monitoring for adverse reactions

Phase 2 (Weeks 3-6): Progressive Loading Period

  • Graduated strengthening exercise protocols
  • Progressive resistance training targeting periarticular musculature[17]
  • Systematic functional exercise progression
  • Proprioceptive and neuromuscular control training

Phase 3 (Week 6+): Optimisation Period

  • Exploitation of the analgesic window to advance exercise intensity parameters
  • Sport-specific or activity-specific training protocols
  • Establishment of sustainable long-term exercise adherence patterns

Primary Physiotherapy Objectives

The therapeutic window established by viscosupplementation should be utilised to:

  • Optimise Muscular Strength: Targeted strengthening of quadriceps musculature (knee OA), hip abductor complex (hip OA), and rotator cuff musculature (shoulder OA)[18]
  • Enhance Movement Quality: Gait retraining protocols, biomechanical optimisation, functional movement pattern refinement
  • Establish Exercise Adherence: Development of consistent exercise behaviours during the improved symptom period

Patient Education and Expectation Management

Expected Outcomes: Patients should anticipate modest symptom reduction rather than complete pain elimination.[19] Typical response patterns include pain intensity reduction from 7/10 to 4/10 on the Visual Analogue Scale, which facilitates improved tolerance of therapeutic exercises and activities of daily living.

Temporal Response Pattern: Gradual symptomatic improvement typically manifests over 2-4 weeks post-injection, with peak therapeutic benefit observed at 8-12 weeks and symptom relief duration of 3-6 months.[20]

Concurrent Exercise Requirements: Optimal therapeutic outcomes are achieved through integration of viscosupplementation with sustained physiotherapy participation.[21] The analgesic window should be strategically utilised to develop strength and functional capacity that persists beyond the duration of injection efficacy.

Therapeutic Limitations: Viscosupplementation provides symptomatic management rather than disease modification.[22] This intervention represents one component of a comprehensive management strategy incorporating therapeutic exercise, weight optimisation, and activity modification principles.[23]

Clinical Decision-Making Framework

Prior to recommending viscosupplementation, systematically verify:[24]

  • Exhaustion of conservative management strategies (minimum 6-8 weeks of supervised physiotherapy, prescribed home exercise programme, appropriate pharmacological trial)[25]
  • Appropriate disease severity profile (Kellgren-Lawrence grade 2-3; exclusion of advanced bone-on-bone pathology)[26]
  • Documented functional impact (VAS >4/10, exercise participation limited by pain, compromised activities of daily living)
  • Patient suitability (absence of contraindications, realistic treatment expectations, demonstrated motivation for ongoing physiotherapy)
  • Consideration of alternative interventions (corticosteroid injections, platelet-rich plasma therapy, orthopaedic surgical consultation)

Outcome Monitoring Framework

2-Week Assessment: Evaluation of adverse reactions, assessment of initial therapeutic response, initiation of progressive loading protocols[27]

6-8 Week Assessment: Quantification of pain and functional changes utilising validated outcome measures (Western Ontario and McMaster Universities Osteoarthritis Index, Visual Analogue Scale, functional performance tests), advancement of exercise intensity parameters[28]

3-4 Month Assessment: Evaluation of sustained therapeutic benefit, documentation of efficacy duration, determination of repeat injection candidacy[29]

Indicators of Therapeutic Success: Achievement of ≥30% pain reduction from baseline values, improved validated outcome scores, enhanced exercise tolerance capacity, reduced analgesic medication consumption

Safety Profile and Tolerability

Viscosupplementation demonstrates a favourable safety profile with minimal adverse event incidence.[30] Minor adverse effects include transient local pain, joint effusion, and localised swelling typically resolving within several days. Rare adverse events may include erythema, pruritus, cephalgia, and low-grade pyrexia. Severe allergic reactions demonstrate extremely low incidence rates.[31] The favourable risk-benefit profile supports its utilisation as a repeatable therapeutic intervention.

Clinical Summary

Viscosupplementation provides optimal therapeutic value when it facilitates patient engagement in exercise-based rehabilitation that would otherwise be precluded by pain intensity.[32] Clinical recommendation is appropriate for patients with moderate knee, hip, or shoulder osteoarthritis who have completed adequate conservative treatment protocols yet continue to experience functionally limiting pain (VAS >4/10) that impedes rehabilitation participation.[33]

Evidence-Based Practice Point: Viscosupplementation functions as a complementary rather than replacement intervention for physiotherapy.[34] The established analgesic window (3-6 months duration) should be strategically utilised to advance exercise intensity parameters and develop sustainable functional capacity that persists beyond the temporal efficacy of the injection. High molecular weight, ultrasound-guided formulations demonstrate optimal therapeutic outcomes.[35][36] Integration with ongoing physiotherapy protocols is essential for achieving optimal long-term clinical outcomes.[37]

References

  1. ↑ Migliore A, Gigliucci G, Alekseeva L, Bannuru RR, Blicharski T, Diracoglu D, Georgiadis A, Hamoud H, Martusevich N, Matucci Cerinic M, Perduk J. Systematic literature review and expert opinion for the use of viscosupplementation with hyaluronic acid in different localizations of osteoarthritis. Orthopedic Research and Reviews. 2021 Dec 2:255-73. Available from: https://pubmed.ncbi.nlm.nih.gov/34880685/
  2. ↑ Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. Available from: https://pubmed.ncbi.nlm.nih.gov/30703329/
  3. ↑ Porta F, Filippucci E, Cipolletta E, et al. Efficacy of a single ultrasound-guided injection of high molecular weight hyaluronic acid combined with collagen tripeptide in patients with knee osteoarthritis and chondrocalcinosis. Front Med. 2024;11:1437160. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1437160/full
  4. ↑ Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9. Available from: https://pubmed.ncbi.nlm.nih.gov/8379730/
  5. ↑ Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. Available from: https://pubmed.ncbi.nlm.nih.gov/25952318/
  6. ↑ Petrella RJ, Decaria J, Petrella MJ. Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatol Rep. 2011;3:16-21.
  7. ↑ Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020;72(2):149-62. Available from: https://pubmed.ncbi.nlm.nih.gov/31908163/
  8. ↑ Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2015;1:CD004376. Available from: https://pubmed.ncbi.nlm.nih.gov/25569281/
  9. ↑ Migliore A, Bizzi E, Herrero-Beaumont J, et al. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap!. Eur Rev Med Pharmacol Sci. 2015;19(7):1124-9. Available from: https://pubmed.ncbi.nlm.nih.gov/25912569/
  10. ↑ Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. Available from: https://pubmed.ncbi.nlm.nih.gov/26367887/
  11. ↑ Chavda S, Rabbani SA, Wadhwa T. Role and Effectiveness of Intra-articular Injection of Hyaluronic Acid in the Treatment of Knee Osteoarthritis: A Systematic Review. Cureus. 2022;14(4):e24503. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9135165/
  12. ↑ Bourgeault-Gagnon Y, Simunovic N, Heels-Ansdell D, et al. Intra-articular injection of a cross-linked hyaluronic acid combined with triamcinolone hexacetonide improves pain at six months in patients with mild to moderate hip osteoarthritis. J ISAKOS. 2025;10:100363. Available from: https://www.sciencedirect.com/science/article/pii/S2059775424002104
  13. ↑ Battaglia AG, D'Apolito R, Labionda F, et al. Ultrasound-Guided Hip Injections with High Density Hyaluronic Acid: Outcome at One Year Follow Up. J Clin Med. 2024;13(9):2515. Available from: https://www.mdpi.com/2077-0383/13/9/2515
  14. ↑ Migliorini F, Schäfer L, Masoni V, et al. Intra-articular injections for shoulder arthritis in adults: a systematic review. Eur J Med Res. 2025;30:1080. Available from: https://link.springer.com/article/10.1186/s40001-025-03423-4
  15. ↑ Deyle GD, Allison SC, Matekel RL, et al. Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys Ther. 2005;85(12):1301-17. Available from: https://pubmed.ncbi.nlm.nih.gov/15673544/
  16. ↑ Uthman OA, van der Windt DA, Jordan JL, et al. Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis. BMJ. 2013;347:f5555. Available from: https://pubmed.ncbi.nlm.nih.gov/24454376/
  17. ↑ Vincent KR, Vincent HK. Resistance exercise for knee osteoarthritis. PM R. 2012;4(5 Suppl):S45-52. Available from: https://pubmed.ncbi.nlm.nih.gov/22632703/
  18. ↑ Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med. 1997;127(2):97-104. Available from: https://pubmed.ncbi.nlm.nih.gov/9428740/
  19. ↑ Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. Available from: https://pubmed.ncbi.nlm.nih.gov/26367887/
  20. ↑ Chavda S, Rabbani SA, Wadhwa T. Role and Effectiveness of Intra-articular Injection of Hyaluronic Acid in the Treatment of Knee Osteoarthritis: A Systematic Review. Cureus. 2022;14(4):e24503. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9135165/
  21. ↑ Deyle GD, Allison SC, Matekel RL, et al. Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys Ther. 2005;85(12):1301-17. Available from: https://pubmed.ncbi.nlm.nih.gov/15673544/
  22. ↑ Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. Available from: https://pubmed.ncbi.nlm.nih.gov/25952318/
  23. ↑ Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020;72(2):149-62. Available from: https://pubmed.ncbi.nlm.nih.gov/31908163/
  24. ↑ Migliore A, Gigliucci G, Alekseeva L, Bannuru RR, Blicharski T, Diracoglu D, Georgiadis A, Hamoud H, Martusevich N, Matucci Cerinic M, Perduk J. Systematic literature review and expert opinion for the use of viscosupplementation with hyaluronic acid in different localizations of osteoarthritis. Orthopedic Research and Reviews. 2021 Dec 2:255-73. Available from: https://pubmed.ncbi.nlm.nih.gov/34880685/
  25. ↑ Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2015;1:CD004376. Available from: https://pubmed.ncbi.nlm.nih.gov/25569281/
  26. ↑ Migliore A, Bizzi E, Herrero-Beaumont J, et al. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap!. Eur Rev Med Pharmacol Sci. 2015;19(7):1124-9. Available from: https://pubmed.ncbi.nlm.nih.gov/25912569/
  27. ↑ Wen DY. Intra-articular Hyaluronic Acid Injections for Knee Osteoarthritis. Am Fam Physician. 2000;62(3):565-70. Available from: https://pubmed.ncbi.nlm.nih.gov/10750978/
  28. ↑ Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. Available from: https://pubmed.ncbi.nlm.nih.gov/26367887/
  29. ↑ Chavda S, Rabbani SA, Wadhwa T. Role and Effectiveness of Intra-articular Injection of Hyaluronic Acid in the Treatment of Knee Osteoarthritis: A Systematic Review. Cureus. 2022;14(4):e24503. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9135165/
  30. ↑ Wen DY. Intra-articular Hyaluronic Acid Injections for Knee Osteoarthritis. Am Fam Physician. 2000;62(3):565-70. Available from: https://pubmed.ncbi.nlm.nih.gov/10750978/
  31. ↑ Pullman-Mooar S, Mooar P, Sieck M, et al. Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections?. J Rheumatol. 2002;29(12):2611-4. Available from: https://pubmed.ncbi.nlm.nih.gov/12465160/
  32. ↑ Uthman OA, van der Windt DA, Jordan JL, et al. Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis. BMJ. 2013;347:f5555. Available from: https://pubmed.ncbi.nlm.nih.gov/24454376/
  33. ↑ Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020;72(2):149-62. Available from: https://pubmed.ncbi.nlm.nih.gov/31908163/
  34. ↑ Deyle GD, Allison SC, Matekel RL, et al. Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys Ther. 2005;85(12):1301-17. Available from: https://pubmed.ncbi.nlm.nih.gov/15673544/
  35. ↑ Petrella RJ, Decaria J, Petrella MJ. Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatol Rep. 2011;3:16-21.
  36. ↑ Porta F, Filippucci E, Cipolletta E, et al. Efficacy of a single ultrasound-guided injection of high molecular weight hyaluronic acid combined with collagen tripeptide in patients with knee osteoarthritis and chondrocalcinosis. Front Med. 2024;11:1437160. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1437160/full
  37. ↑ Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. Available from: https://pubmed.ncbi.nlm.nih.gov/30703329/
Retrieved from "https://www.physio-pedia.com/w/index.php?title=Viscosupplementation_For_Osteoarthritis&oldid=374989"